Prenatal Cannabis Use Tied to Adverse Maternal Health Outcomes
Medically reviewed by Drugs.com.
By Lori Solomon HealthDay Reporter
THURSDAY, July 25, 2024 -- Prenatal cannabis use is associated with several adverse maternal health outcomes during pregnancy, according to a study published July 22 in JAMA Internal Medicine.
Kelly C. Young-Wolff, Ph.D., from Kaiser Permanente Northern California in Oakland, and colleagues evaluated whether prenatal cannabis use (self-reported use during early pregnancy or a positive toxicology test result based on universal screening) is associated with maternal health outcomes during pregnancy. Analysis included 316,722 pregnancies (January 2011 to December 2019) among 250,221 unique individuals.
The researchers found that 6.3 percent of individuals screened positive for prenatal cannabis use (2.9 percent by self-report, 5.3 percent by toxicology testing, and 1.8 percent by both). Cannabis use frequency was daily for 0.6 percent, weekly for 0.7 percent, monthly or less for 1.5 percent, and unknown for 3.4 percent. Greater risk of gestational hypertension (adjusted risk ratio [aRR], 1.17), preeclampsia (aRR, 1.08), weight gain less than guidelines (aRR, 1.05), weight gain greater than guidelines (aRR, 1.09), and placental abruption (aRR, 1.19) were associated with prenatal cannabis use. Similar results were seen for use determined by self-report only or toxicology testing only.
"Continued research is needed to understand whether characteristics of prenatal cannabis use (e.g., dose, mode, and timing) moderate these associations," the authors write.
Editorial (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2024-07-26 07:15
Read more
- Reducing Sedentary Time, Increasing Standing Does Not Reduce BP
- Primary Care Encounter Notes Often Lack Thoroughness
- AHA: Rural-Urban Disparities Persist in Cardiovascular Mortality
- Mpox Spread in Congo May Be Slowing
- Chronic Joint Pain Plus Depression Can Take Toll on the Brain
- Men Aged >16 to to <55 years at increased risk for acute kidney injury (AKI)
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions